Schrodinger Inc (SDGR) Stock Price, Quote & News

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focu...

Industry: Health Information Services

Sector: Healthcare

Phone: 212 295 5800

Website: www.schrodinger.com

Address:

1540 Broadway, 24th Floor, New York, United States

BB_88_ Jul. 2 at 7:23 PM

$SDGR short 17.15 in to close

0 · Reply

bambus3001 Jul. 2 at 2:07 PM

$SDGR Siehste die Profis halten ihre Stücke fest ,und Schwupp rennt es wieder

0 · Reply

Trader_Ty Jul. 2 at 1:44 PM

$SDGR key watch today for an add

1 · Reply

bambus3001 Jul. 1 at 8:22 PM

$SDGR Wer da wohl fleissig weiter einsammelt und das von wem. Ein Buy out wäre auch denkbar ,dann aber locker 40 $ pro Aktie.

0 · Reply

BB_88_ Jul. 1 at 5:34 PM

$SDGR playing the other way - bought some here

0 · Reply

beckman07 Jul. 1 at 2:35 PM

$SDGR Super, super, super weak

0 · Reply

bambus3001 Jul. 1 at 1:33 PM

$SDGR Gut erkannt ,platz nach oben bis 26

1 · Reply

Trader_Ty Jul. 1 at 1:27 PM

$SDGR 16.5 key pivot

0 · Reply

bambus3001 Jul. 1 at 9:34 AM

$SDGR kurz durchatmen ist grade angesagt ,bevor die Reise wohin geht ? Zieht euch alle warm an denn dort ist es ????

0 · Reply

The_Matrix_reloaded_2020 Jul. 1 at 6:21 AM

$SDGR 👀 Nice dip. Bought more

0 · Reply

Schrödinger Transcript: AGM 2026

2026-06-18T12:54:39.000Z - 16 days ago

Schrodinger reports inducement grants under Nasdaq listing rule

Jun 18, 2026, 8:30 AM EDT - 16 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 19, 2026, 2:05 PM EDT - 6 weeks ago

Schrödinger Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-14T16:24:26.000Z - 7 weeks ago

Schrodinger price target lowered to $17 from $19 at Morgan Stanley

May 13, 2026, 5:20 PM EDT - 7 weeks ago

Schrödinger Transcript: Bank of America Global Healthcare Conference 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Schrödinger Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Schrödinger Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Schrödinger Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Schrödinger Slides: Q1 2026

May 5, 2026, 4:05 PM EDT - 2 months ago

Schrödinger Reports First Quarter 2026 Financial Results

May 4, 2026, 8:30 AM EDT - 2 months ago

Schrödinger to Participate in Upcoming Investor Conferences

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Schrödinger Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Schrödinger Proxy statement: Proxy filing

Apr 21, 2026, 8:30 AM EDT - 2 months ago

Schrödinger to Announce First Quarter 2026 Financial Results on May 5

2026-04-17T12:52:03.000Z - 2 months ago

Schrodinger reports inducement grants under Nasdaq listing rule

2026-04-13T10:44:45.000Z - 2 months ago

Schrodinger price target lowered to $20 from $25 at KeyBanc

Mar 17, 2026, 9:00 AM EDT - 3 months ago

Schrödinger Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

2026-03-17T12:40:30.000Z - 3 months ago

Schrodinger price target lowered to $13 from $18 at UBS

Mar 10, 2026, 1:40 PM EDT - 4 months ago

Schrödinger Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 9:50 AM EST - 4 months ago

Schrödinger Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-26T14:49:36.000Z - 4 months ago

Schrodinger price target lowered to $20 from $24 at BofA

2026-02-25T21:49:18.000Z - 4 months ago

Schrodinger reports FY25 EPS ($1.41) vs. ($2.57) last year

Feb 25, 2026, 4:30 PM EST - 4 months ago

Schrödinger Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Schrödinger Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Schrödinger Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Schrödinger Slides: Q4 2025

Feb 25, 2026, 4:05 PM EST - 4 months ago

Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 8:30 AM EST - 5 months ago

Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

Jan 12, 2026, 8:30 AM EST - 6 months ago

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

2026-01-09T12:13:36.000Z - 6 months ago

Schrodinger announces collaboration with Lilly TuneLab

LLY

Jan 9, 2026, 7:04 AM EST - 6 months ago

Schrodinger to offer Eli Lilly's AI drug discovery platform on its software

LLY

Jan 9, 2026, 7:00 AM EST - 6 months ago

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

2026-01-08T14:41:54.000Z - 6 months ago

Schrodinger price target lowered to $24 from $33 at TD Cowen

2026-01-08T12:47:13.000Z - 6 months ago

Schrodinger price target raised to $19 from $18 at Morgan Stanley

2026-01-08T12:46:07.000Z - 6 months ago

Schrodinger price target lowered to $25 from $28 at KeyBanc

2026-01-07T13:27:32.000Z - 6 months ago

Schrodinger initiated with a Neutral at UBS

2025-12-15T11:30:24.000Z - 7 months ago

BofA shakes up ratings in Biopharma Services with seven changes

AVTR CRL ICLR MTD RVTY ZTS

2025-12-15T11:25:26.000Z - 7 months ago

Schrodinger upgraded to Buy from Neutral at BofA

2025-12-15T11:16:32.000Z - 7 months ago

Schrodinger upgraded to Buy from Neutral at BofA

Nov 19, 2025, 11:00 AM EST - 8 months ago

Schrödinger Transcript: Jefferies London Healthcare Conference 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Schrödinger to Present at Jefferies London Healthcare Conference

Nov 5, 2025, 4:30 PM EST - 8 months ago

Schrödinger Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Schrödinger Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Schrödinger Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Schrödinger Slides: Q3 2025

Nov 5, 2025, 4:05 PM EST - 8 months ago

Schrödinger Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:30 AM EDT - 8 months ago

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Oct 22, 2025, 8:30 AM EDT - 9 months ago

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Sep 8, 2025, 11:30 AM EDT - 10 months ago

Schrödinger Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 8:30 AM EDT - 11 months ago

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Schrödinger Announces Discontinuation of SGR-2921 Program

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Schrödinger Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Schrödinger Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Schrödinger Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Schrödinger Slides: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 11 months ago

Schrödinger Reports Second Quarter 2025 Financial Results

Jul 25, 2025, 8:30 AM EDT - 1 year ago

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Jul 18, 2025, 10:25 AM EDT - 1 year ago

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Jul 17, 2025, 8:00 AM EDT - 1 year ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

$Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia$

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 18, 2025, 12:00 PM EDT - 1 year ago

Schrödinger Transcript: AGM 2025

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Transcript: Status Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Press release: Status Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Slides: Status Update

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 4, 2025, 1:25 PM EDT - 1 year ago

Schrödinger Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 5:00 PM EDT - 1 year ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 28, 2025, 12:22 PM EDT - 1 year ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

May 22, 2025, 8:30 AM EDT - 1 year ago

Schrödinger to Present at Jefferies Global Healthcare Conference

May 20, 2025, 6:30 AM EDT - 1 year ago

Schrödinger Announces CFO Appointment

May 14, 2025, 4:40 PM EDT - 1 year ago

Schrödinger Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 9:30 AM EDT - 1 year ago

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 7, 2025, 4:30 PM EDT - 1 year ago

Schrödinger Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Schrödinger Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Schrödinger Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Schrödinger Slides: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 5, 2025, 8:30 AM EDT - 1 year ago

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Schrödinger Proxy statement: Proxy Filing

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Mar 18, 2025, 9:00 AM EDT - 1 year ago

Schrödinger Transcript: KeyBanc Annual Health Care Forum 2025

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Schrödinger Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

BB_88_ Jul. 2 at 7:23 PM

$SDGR short 17.15 in to close

0 · Reply

bambus3001 Jul. 2 at 2:07 PM

$SDGR Siehste die Profis halten ihre Stücke fest ,und Schwupp rennt es wieder

0 · Reply

Trader_Ty Jul. 2 at 1:44 PM

$SDGR key watch today for an add

1 · Reply

bambus3001 Jul. 1 at 8:22 PM

$SDGR Wer da wohl fleissig weiter einsammelt und das von wem. Ein Buy out wäre auch denkbar ,dann aber locker 40 $ pro Aktie.

0 · Reply

BB_88_ Jul. 1 at 5:34 PM

$SDGR playing the other way - bought some here

0 · Reply

beckman07 Jul. 1 at 2:35 PM

$SDGR Super, super, super weak

0 · Reply

bambus3001 Jul. 1 at 1:33 PM

$SDGR Gut erkannt ,platz nach oben bis 26

1 · Reply

Trader_Ty Jul. 1 at 1:27 PM

$SDGR 16.5 key pivot

0 · Reply

bambus3001 Jul. 1 at 9:34 AM

$SDGR kurz durchatmen ist grade angesagt ,bevor die Reise wohin geht ? Zieht euch alle warm an denn dort ist es ????

0 · Reply

The_Matrix_reloaded_2020 Jul. 1 at 6:21 AM

$SDGR 👀 Nice dip. Bought more

0 · Reply

The_Matrix_reloaded_2020 Jul. 1 at 6:18 AM

$SDGR Claude Science an Schrodinger products are not competing they are complimentary and serve different purposes in the drug discovery and l8fe sciences pipeline. I guess it will take investors a while to realise this.. https://app.dealroom.co/news/feed/schr-dinger-partners-with-anthropic-on-ai-integration-shifts-75-contracts-to-cloud

1 · Reply

beckman07 Jul. 1 at 1:12 AM

$SDGR My goodness, has Bunsen AI been made obsolete by Claude Science before it even launched?

1 · Reply

madnessofcrowds Jun. 30 at 7:10 PM

$SDGR bought some 16.17

0 · Reply

madnessofcrowds Jun. 30 at 6:59 PM

$SDGR haha people think an LLM can replace computational chemistry expertise

0 · Reply

EthansStocks Jun. 30 at 6:09 PM

$SDGR Crashing today due to Claude Science

1 · Reply

BB_88_ Jun. 30 at 4:50 PM

$SDGR consolidation and crash

1 · Reply

BB_88_ Jun. 30 at 4:39 PM

$SDGR short 17.64 in to close

1 · Reply

bambus3001 Jun. 30 at 3:21 PM

$SDGR Wochenchart zeigt weiter Trend aufwärts, Hier ist ein längerer Atem von Nöten ,aber wir werden über Jahre hinweg deutlich wachsen . 2030 mein Kursziel 120-150 €!!

1 · Reply

BB_88_ Jun. 30 at 2:37 PM

$SDGR short 600

0 · Reply

Weber10 Jun. 30 at 1:07 PM

$SDGR Ajax-Deal abgeschlossen ... 57 Mio. $ an SDGR

0 · Reply

Hairoglyphics Jun. 30 at 12:50 PM

$TELIF if you read my thesis https://skydeckconnect.com/telescope-innovations-telif you would have noticed a tiny mention of a playbook that was run by a company that is ahead of Telescope on IP partnerships. That company, Schrödinger $SDGR , is on a transition to using centralized AI for drug discovery and has been on a bit of surge lately, recovering from steep drops and trading at still reasonable P/S. It’s been part of the recent breakout in biotech stocks.

0 · Reply

scott52 Jun. 30 at 12:20 AM

$SDGR Just two more dollars and the stock will be back to where it was at the start of the year. Yippee.

0 · Reply

Market Cap	1.25B
Revenue (ttm)	255.87M
Net Income (ttm)	-103.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-40.36%
Debt to Equity Ratio	0.00

Volume	1,511,500
Avg Vol	1,492,106
Day's Range	N/A - N/A
Shares Out	73.83M
Stochastic %K	68%
Beta	1.62
Analysts	Strong Sell
Price Target	$20.89